Pharma Focus Asia

Novel Cancer Immunotherapy Tiragolumab Discovered for the Treatment of Non-Small Cell Lung Cancer

Tiragolumab, a novel cancer immunotherapy discovered for the treatment of metastatic Non-small Cell Lung Cancer (NSCLC). Tiragolumab, is the first anti-TIGIT molecule introduced to bind with TIGIT, a protein receptor on immune cells. It functions as an immune amplifier, by improving the body’s immune response. By combining with TIGIT, tiragolumab blocks the interface with a poliovirus receptor (PVR, or CD155) a protein receptor which can suppress the body’s immune response.   

TIGIT blocks the interaction with a protein called poliovirus receptor (PVR, or CD155) which can suppress the body’s immune response.

Tecentriq is a cancer immunotherapy which has the ability to bind with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. Tiragolumab combined with Tecentriq has shown efficacy and safety in PD-L1-positive metastatic NSCLC based on data from the phase II CITYSCAPE trial.

US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for anti-TIGIT tiragolumab in combination with Tecentriq® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC).

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024